GALT实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (27 Apr 2024 @ 04:00):

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases...

Stats
今日成交量	173 828
平均成交量	153 496
市值	213.57M
EPS	$0 ( 2024-04-04 )
下一个收益日期	( $0 ) 2024-05-13
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-4.66
ATR14	$0.0130 (0.38%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-24	Lewis Joel	Buy	1 000	Common Stock
2023-12-31	Czirr James C	Buy	0
2024-04-22	Czirr James C	Sell	21 323	Common Stock
2024-04-23	Czirr James C	Sell	3 677	Common Stock
2024-04-22	Freeman Kevin D	Buy	2 500	Common Stock

INSIDER POWER
24.13
Last 97 transactions
Buy: 4 256 891 \| Sell: 2 389 317

音量相关性

長: 0.23 (neutral)

短: -0.75 (moderate negative)

Signal:(40.806) Neutral

Galectin Therapeutics Inc 相关性

10 最正相关
BRACU	0.946
KIN	0.945
ALGM	0.929
ACVA	0.929
NCAC	0.925
CLBT	0.921
PEGA	0.92
NSIT	0.92
AMYT	0.919
SRRA	0.919

10 最负相关
DCRC	-0.928
AHPI	-0.923
IMV	-0.922
NCBS	-0.921
TENX	-0.92
LAWS	-0.919
CFMS	-0.919
TSHA	-0.918
VWE	-0.917
SGLB	-0.914

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Galectin Therapeutics Inc 相关性 - 货币/商品

0.47
( neutral )

0.67
( moderate )

0.00
( neutral )

-0.37
( neutral )

-0.17
( neutral )

-0.87
( strong negative )

Galectin Therapeutics Inc 财务报表

Annual	2023
营收:	$0
毛利润:	$-33 000.00 (0.00 %)
EPS:	$-0.680

FY	2023
营收:	$0
毛利润:	$-33 000.00 (0.00 %)
EPS:	$-0.680

FY	2022
营收:	$0
毛利润:	$-32 000.00 (0.00 %)
EPS:	$-0.660

FY	2021
营收:	$0.00
毛利润:	$0.00 (0.00 %)
EPS:	$-0.520

Financial Reports:

No articles found.

Galectin Therapeutics Inc

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer. It also engages in developing GM-CT-01, which is in pre-clinical development stage for the treatment of cardiac and vascular fibrosis, as well as focuses on developing belapectin for the treatment of psoriasis, and lung and kidney fibrosis. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.